sub:assertion { d:DB04991v:identifier "DB04991" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB04991" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB04991> ; dv:drugbank-id "DB04991" ; dv:x-cas <http://bio2rdf.org/cas:> ; dct:description "XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles. It is being developed by Exelixis, Inc."@en ; dct:identifier "drugbank:DB04991" ; dct:title "XL784"@en ; adv:Drug ; rdfs:label "XL784 [drugbank:DB04991]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB04991> . }